A detailed history of Cinctive Capital Management LP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Cinctive Capital Management LP holds 74,341 shares of BPMC stock, worth $6.59 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares
74,341
Previous 67,502 10.13%
Holding current value
$6.59 Million
Previous $7.28 Million 5.53%
% of portfolio
0.4%
Previous 0.36%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$84.1 - $120.5 $575,159 - $824,099
6,839 Added 10.13%
74,341 $6.87 Million
Q2 2024

Aug 14, 2024

BUY
$85.18 - $108.78 $779,993 - $996,098
9,157 Added 15.69%
67,502 $7.28 Million
Q1 2024

May 15, 2024

BUY
$73.17 - $99.79 $4.05 Million - $5.53 Million
55,375 Added 1864.48%
58,345 $5.53 Million
Q4 2023

Feb 14, 2024

BUY
$43.96 - $92.84 $130,561 - $275,734
2,970 New
2,970 $273,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.3B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Cinctive Capital Management LP Portfolio

Follow Cinctive Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cinctive Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Cinctive Capital Management LP with notifications on news.